Novo Company Profile
What is the competitive landscape for NOVO
NOVO has eleven approved drugs.
There are forty-nine US patents protecting NOVO drugs.
Summary for Novo
| US Patents: | 49 |
| Tradenames: | 12 |
| Ingredients: | 6 |
| NDAs: | 11 |
| Patent Litigation for Novo: | See patent lawsuits for Novo |
Drugs and US Patents for Novo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | TABLET;ORAL | 213051-006 | Dec 9, 2024 | RX | Yes | Yes | 10,278,923 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | DISCN | Yes | No | 8,129,343 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novo | OZEMPIC | semaglutide | TABLET;ORAL | 213051-004 | Dec 9, 2024 | RX | Yes | Yes | 10,278,923 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | 8,536,122 | ⤷ Start Trial |
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-004 | Oct 6, 2022 | 8,579,869 | ⤷ Start Trial |
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-001 | Jun 4, 2021 | 8,536,122 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
| ➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
International Patents for Novo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2868188 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2006045526 | ⤷ Start Trial |
| Portugal | 3448416 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | 1490067-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918 |
| 2498758 | PA2020003 | Lithuania | ⤷ Start Trial | PRODUCT NAME: METFORMINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111 |
| 1506211 | 179 5017-2014 | Slovakia | ⤷ Start Trial | PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
